首页> 外文期刊>Clinical Laboratory >Determination of β_2-Microglobulin in Biological Samples Using an Immunoenzymometric Assay (Chemiluminescence Detection) or an Immunoturbidimetric Assay: Comparison with a Radioimmunoassay
【24h】

Determination of β_2-Microglobulin in Biological Samples Using an Immunoenzymometric Assay (Chemiluminescence Detection) or an Immunoturbidimetric Assay: Comparison with a Radioimmunoassay

机译:使用免疫比浊法(化学发光检测)或免疫比浊法测定生物样品中的β_2-微球蛋白:与放射免疫法的比较

获取原文
获取原文并翻译 | 示例
           

摘要

Monitoring β_2-microglobulin (β2M) in biological fluids has gained considerable interest in pathologies such as haematologic malignancies, renal diseases, and chronic inflammatory diseases. Due to limitations of the RIA in the routine laboratory, we measure β2M with non-isotopic methods. 189 patients suffering from myeloma (n=66), end stage renal failure (n=54) or inflammation (n=69) were included in this study. β2M was determined in serum, urine and dialysate using an immunoenzymometric assay with Chemiluminescence detection [Immulite Diagnostic Products Corporation (DPC), La Garenne Colombes, France] and an immunoturbidimetric assay (Olympus, Rungis, France). The data were compared with a radioimmunoassay (Immunotech, Marseille, France) taken as a reference. Using serum samples, the immunoenzymometric assay with Chemiluminescence detection and the immunoturbidimetric assay have reliable analytical performances. Values obtained with serum samples are highly correlated with the radioimmunoassay (DPC/RIA r~2=0.84; Olympus/RIA r~2=0.94) whatever the type of pathology; however an over-estimation which could be related to cross reactivity with β2M fragments was observed with the RIA method as suggested by crossover calibration and recovery studies. Values obtained with urinary samples (n=96) are closely related to those obtained with the RIA (DPC/RIA r~2 = 0.98; Olympus/RIA: r~2=0.99). Despite the low levels observed in dialysate (n=S7) good correlations were observed between Olympus vs DPC (r~2=0.85). By contrast, the two non-isotope methods are poorly related with the RIA method (DPC vs RIA r2=0.47 and Olympus vs RIA r~2=0.54). In conclusion, the immunoenzymometric assay with Chemiluminescence detection or the immunoturbidimetric assay could be used in the routine laboratory in order to determine β2M in plasma, urine and dialysate.
机译:监测生物流体中的β_2-微球蛋白(β2M)在诸如血液系统恶性肿瘤,肾脏疾病和慢性炎症性疾病等病理学中引起了极大的兴趣。由于常规实验室中RIA的局限性,我们使用非同位素方法测量β2M。这项研究包括189例患有骨髓瘤(n = 66),终末期肾衰竭(n = 54)或炎症(n = 69)的患者。使用具有化学发光检测功能的免疫酶测定法[Immulite Diagnostic Products Corporation(DPC),法国La Garenne Colombes]和免疫浊度测定法(Olympus,Rungis,法国)测定血清,尿液和透析液中的β2M。将数据与放射免疫测定法(法国马赛的免疫技术)进行比较。使用化学发光检测的免疫酶测定法和免疫浊度测定法使用血清样品具有可靠的分析性能。无论病理类型如何,血清样品获得的值与放射免疫测定高度相关(DPC / RIA r〜2 = 0.84; Olympus / RIA r〜2 = 0.94)。然而,如交叉定标和回收率研究建议的那样,使用RIA方法观察到过高估计值可能与与β2M片段的交叉反应性有关。用尿液样本(n = 96)获得的值与用RIA获得的值密切相关(DPC / RIA r〜2 = 0.98; Olympus / RIA:r〜2 = 0.99)。尽管在透析液中观察到低水平(n = S7),但在奥林巴斯与DPC之间观察到良好的相关性(r〜2 = 0.85)。相比之下,两种非同位素方法与RIA方法的关联性较差(DPC与RIA r2 = 0.47和Olympus与RIA r〜2 = 0.54)。总之,可以在常规实验室中使用化学发光检测的免疫酶分析法或免疫比浊法测定血浆,尿液和透析液中的β2M。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号